Stockreport

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics, Inc.  (LXEO) 
PDF Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Complete [Read more]